Exploring disease-modifying therapies and precision medicine in type 1 diabetes
Watch the full video on YouTube to explore the latest findings from two major clinical trials investigating disease-modifying therapies for type 1 diabetes.
In this episode, Prof. Chantal Mathieu (KU Leuven, endocrinologist and leading researcher in type 1 diabetes) and Prof. Francesco Dotta (University of Siena, expert in type 1 diabetes pathophysiology and clinical trials) discuss the MELD-ATG and VERA-T1D trials conducted through the European INNODIA consortium.
Topics include:
The goals of the INNODIA consortium and its role in advancing type 1 diabetes research
The VERA-T1D trial, testing verapamil as a potential beta-cell protective therapy
Why the trial narrowly missed its primary endpoint but still provides important clinical insights
The MELD-ATG adaptive trial, identifying a low-dose immunotherapy that can delay beta-cell decline
How innovative trial designs allow researchers to optimise dosing strategies
The importance of biomarkers and precision medicine approaches in type 1 diabetes
Explore the latest EASD Annual Meeting presentations and learn more about our expert speakers:
Prof. Chantal Mathieu
Prof. Francesco Dotta
For more expert conversations, explore our podcast archive.
